Table 2 Univariate and multivariate analysis for G3 + MACEs

Age

1.03

0.27

PS

0.91

 0 vs. 1

1.34

0.64

 0 vs. 2

1.74

0.46

 0 vs. 3

3.87E-09

1.00

Obesity

0.07

0.27

 BMI < 25 vs. 25–30

4.28

0.03

2.23

0.30

 BMI < 25 vs. ≥ 30

2.93

0.07

2.99

0.11

CV risk

0.57

 I vs. II

0.31

0.37

 I vs. III

0.47

0.55

Heart failure, Yes vs. No

6

0.009

4.61

0.30

Valvulopathy, Yes vs. No

2.12

0.21

Heart rhythm disorders, Yes vs. No

2.76

0.04

1.01

0.99

PHT, Yes vs. No

2.37

0.08

1.89

0.28

LVEF

0.94

0.03

1.01

0.88

Location

0.14

0.10

 Cervical vs. superior

0.59

0.72

0.36

0.50

 Cervical vs. middle

4

0.21

2.28

0.48

 Cervical vs. inferior

1.28

0.83

0.29

0.35

 Cervical vs. esogastric junction

4

0.25

1.27

0.85

RT technique, 3DCRT vs. VMAT

1.31

0.58

CT-RT, Yes vs. No

1.53

0.59

CTV-LR dose (Gy)

0.90

 < 40 vs. 40–45

1.34

0.79

< 40 vs. ≥ 45

1.07

0.95

CTV-HR dose (Gy), < 60 vs. ≥ 60

0.89

0.81

V15LA, ≤ or > 76,5 cc

5.21

0.001

6.97

0.01

MHD (Gy)

1.01

0.51

5FU / Herceptin during induction CT or CT-RT, Yes vs. No

0.69

0.45

5FU / Herceptin at all time, Yes vs. No

0.91

0.86

CT during CT-RT

0.44

 None vs. 5FU

7

0.08

 None vs. Carboplatin

2.63

0.28

 None vs. Carboplatin-5FU

2.33

0.54

 None vs. Cisplatin

4.33E-09

1

 None vs. Cisplatin-5FU

1.4

0.72

 None vs. FOLFOX

0.81

0.82

 None vs. Taxol

4.33E-09

1.00